In clinic, recent studies showed a significant benefit of bevacizumab (Avastin®) in the treatment of primary brain tumors, as shown by Vredenburgh et al. for patients with recurrent gliomas; these data confirm a synergic effect with chemotherapy. Similarly, a potential synergic action in a combined approach with radiation therapy seems to be an interesting therapeutic way.